Integrated DNA Technologies Acquires ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation

Rhea-AI Summary

Integrated DNA Technologies (IDT) has acquired Invitae's Archer® Next Generation Sequencing (NGS) research assays for approximately $48 million. This strategic purchase aims to enhance IDT’s oncology research capabilities, allowing labs to identify biomarkers and boost cancer research. The acquisition includes a license to Invitae’s AMP™ technology, and the NGS assays are expected to integrate smoothly with IDT's existing xGen™ offerings, which have experienced significant growth since 2019. The deal also adds over 100 new associates globally to IDT’s workforce.

Positive

• Acquisition of Archer NGS research assays enhances IDT's oncology research capabilities.
• Transaction valued at approximately $48 million, indicating a valuable investment in NGS technology.
• Over 100 new associates added, expanding IDT's workforce and expertise.
• Integration expected to complement IDT’s existing xGen NGS portfolio, enabling all-in-one solutions.

Negative

• None.

Addition of next generation sequencing research panels, bioinformatics, positions IDT to become a leading oncology research solutions provider

CORALVILLE, Iowa--(BUSINESS WIRE)-- Integrated DNA Technologies, Inc. (IDT) today announced it closed on the purchase of Next Generation Sequencing (NGS) research assays from Invitae Corporation (NYSE: NVTA) under the trademarked name Archer®. The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with an all-in-one solution to uncover biomarkers and advance cancer discoveries. The transaction enables IDT to expand its existing operations, build upon the legacy Archer portfolio, and welcome more than 100 new associates globally.

“The acquisition of the NGS research assays aligns with our focus to accelerate the pace of scientific discovery, laying the foundation for IDT to become a leading oncology research solutions provider,” said Demaris Mills, president, IDT. “The products, tools, talent and licensed technology will enable us to grow our NGS platform and unlock new market opportunities for IDT.”

IDT Invests in NGS Assay Offerings and Enhanced Informatics Capabilities

The acquired NGS research assays are powered by Invitae’s Anchored Multiplex PCR (AMP™) technology and bring new capabilities, including an enhanced bioinformatics platform and expertise, to expand IDT’s xGen™ NGS suite of solutions. The company’s NGS bioinformatics offerings will provide customers with an end-to-end solution to accelerate their projects from bench to analysis. The NGS research assays, which consist of VariantPlex™, FusionPlex™, LiquidPlex™, and Immunoverse™ panels, will continue to be manufactured and produced out of the Boulder, Colo. facility.

Mills added, “Coupled with IDT’s existing xGen NGS portfolio, this acquisition will enable IDT to provide researchers with all-in-one NGS research solutions to uncover novel biomarkers, including critical cancer fusions.”

Transaction Details

IDT purchased Archer NGS research assays—which reported high double-digit growth since 2019—from Invitae for cash consideration of approximately $48 million, subject to certain adjustments. The transaction is structured as an asset deal and includes a license to intellectual property related to the AMP technology. The NGS research assays were formally known as Invitae’s Research Use Only (RUO) kitted solutions.

About IDT

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP* services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore. For more information, please visit www.idtdna.com and follow us on Twitter, LinkedIn, Facebook, YouTube, and Instagram.

Disclaimer: RUO—For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. *GMP refers to products manufactured under ISO 13485: 2016 QMS. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005276/en/

Kristina Sarenas

Manager of PR

800-328-2661 (USA & Canada)

+1 319-626-8400 (outside USA)

idtpr@idtdna.com

Source: Integrated DNA Technologies, Inc.

FAQ

What did IDT acquire from Invitae Corporation?

IDT acquired the Archer® Next Generation Sequencing (NGS) research assays from Invitae Corporation.

How much did IDT pay for the acquisition of Archer NGS research assays?

IDT paid approximately $48 million for the acquisition.

What technologies are included in the acquisition from Invitae?

The acquisition includes Invitae's Anchored Multiplex PCR (AMP™) technology and NGS research assays.

How does the acquisition affect IDT's business operations?

The acquisition is expected to enhance IDT's oncology research capabilities and expand its market opportunities.

What growth has the Archer NGS research assays experienced since 2019?

The Archer NGS research assays have reported high double-digit growth since 2019.